L3VLUP
ProSign in

TNGX in the 13F filings

Tango Therapeutics Inc · CUSIP 87583X109

Sector · Pharmaceuticals and biotechnologyTheme · Healthcare: biopharma and medtech· L3VLUP-definedTheme · Pharmaceutical preparations
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q2 2024Q3 2023Q2 2023Q1 2023Q4 2022
Quarter end
30 Jun 2023
the date the book describes
Filed
14 Aug 2023
up to 45 days after the quarter end
Managers listing it
1
at least, of 95 tracked, among listed positions
Comparable managers
93
filed both Q1 2023 and Q2 2023; 1 listed it in both
Shares listed
263,645
combined, among listed positions
Reported value
$875k
combined, at the quarter end

Managers listing TNGX in Q2 2023

Share of 13F value is the position’s reported value over everything the manager reported that quarter. The share change is against Q1 2023, and only where both filings list the position. A rise in value with no rise in shares is the price, not buying.

1 of 1 holder

ActionFiling
Woodline Partners LP263,645$875kunder 0.1%Trimmed-97,54914 Aug 2023 (the filing on sec.gov)

Largest increases and reductions, by shares

Q1 2023 to Q2 2023, among managers that listed it in both quarters or opened it.

Increases

No increase among listed positions.

Reductions

New positions and exits

At least these many: a manager is shown exiting only where its own filing shows the position gone.

New (0)

No new position among listed positions.

Exited (0)

No exit shown by a manager’s own filing.

Ownership over time

Every quarter on file. A quarter-end value moves with the price as well as with the shares held; buyers and sellers count comparable managers, by shares.
1 in Q2 2024 to 5 in Q2 2026

Tracked managers listing it, at least.

02462022202320252026
the quarter shown share split complete books; unmarked quarters rest on listed positionsClick a quarter to open it.
TNGX by quarter
QuarterHoldersReported valueBuyersSellers
Q3 20212$10mn.a.n.a.
Q4 20212$8.8mn.a.n.a.
Q1 20222$6.1mn.a.n.a.
Q2 20222$3.6mn.a.n.a.
Q3 20222$2.9mn.a.n.a.
Q4 20222$4.6mn.a.n.a.
Q1 20231$1.4mn.a.n.a.
Q2 20231$875kn.a.n.a.
Q3 20231$2.8mn.a.n.a.
Q2 20241$3.0m10
Q4 20241$12m10
Q1 20251$6.3m10
Q2 20252$78m20
Q3 20253$166m30
Q4 20253$252m1410
Q1 20265$570m1413
Q2 20265$805m1611

Compare with…

Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.

TNGX and LLY →TNGX and JNJ →TNGX and VRTX →Choose a stock to compare with TNGX →

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.

Which funds own TNGX, latest filings →Back to the 13F Explorer →